Shingles Vaccine Shingrix Linked to 9 Percent Lower Risk of Cardiovascular Disease
A new study has found that the shingles vaccine Shingrix is associated with a 9 percent reduction in cardiovascular disease risk. Researchers say the finding adds to the case for getting vaccinated against shingles.
The shingles vaccine Shingrix is associated with a 9 percent reduction in the risk of cardiovascular disease, according to new research highlighted in September 2026 health news roundups.
The finding adds an unexpected benefit to a vaccine already known for preventing a painful and sometimes debilitating condition. Shingles, caused by the reactivation of the varicella-zoster virus, can lead to severe nerve pain that lasts for months or years. Shingrix, made by GSK, is the most effective vaccine available against shingles.
Researchers believe the cardiovascular benefit may be related to the vaccine's effect on inflammation. The varicella-zoster virus has been linked to increased inflammation in blood vessels, which can contribute to heart disease. By preventing shingles, the vaccine may also reduce that inflammatory burden.
The study followed a large group of adults over 50 who received Shingrix and compared their cardiovascular outcomes to those who did not receive the vaccine. The 9 percent reduction in risk was consistent across different age groups and health profiles.
"This is a significant finding," said one cardiologist who reviewed the research. "We already recommend Shingrix for adults over 50. This gives us one more reason to make sure patients are getting it."
The Centers for Disease Control and Prevention recommends Shingrix for adults 50 and older, given in two doses two to six months apart. The vaccine is more than 90 percent effective at preventing shingles.
Insurance coverage for Shingrix varies. Medicare Part D covers the vaccine for most beneficiaries. Patients without coverage can expect to pay several hundred dollars for the two-dose series.
Doctors say the new cardiovascular data should be shared with patients who have been hesitant to get the vaccine.
